# Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

> **NCT01639131** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Colorectal Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Filgrastim or Pegfilgrastim

## Key facts

- **NCT ID:** NCT01639131
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-10
- **Primary completion:** 2016-10-03
- **Final completion:** 2019-03-11
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01639131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01639131, "Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01639131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*